Positive Performance in Third Quarter 2025
The Tecan Group today offered insights into its performance for the third quarter of 2025, showcasing notable achievements amidst evolving market conditions. As a leader in laboratory automation, Tecan has managed to record a mid-single-digit growth in sales during this quarter, signaling a positive shift from previous declines in earlier months.
Segment Highlights
Within the company's segments, significant developments are occurring. The Life Sciences Business experienced a minor decline in sales, while the Partnering Business saw impressive growth, reaching a rise in the low teens percentage range. This growth in the Partnering Business is particularly encouraging, reflecting the company’s strategic focus on collaborations that have proven fruitful.
Order Intake and Book-to-Bill Ratio
A vital indicator of future performance, the order intake for Tecan’s businesses exceeded sales throughout the third quarter. Keeping the business's sustainability in view, the book-to-bill ratio remained robust at above 1, assuring stakeholders of an optimistic outlook.
Full-Year 2025 Outlook Confirmed
Despite the variability in market conditions, Tecan has confirmed its full-year 2025 sales outlook. Sales are projected to remain within a specific range—from a low-single-digit decline to low-single-digit growth. Importantly, current trends suggest that the company’s performance is likely to fall in the lower half of this range, yet still maintains a positive trajectory.
Challenges in Key Markets
The company has noted some challenges, particularly in the US Academia & Government sector where sales are aligning with initial projections. In the Chinese market, however, demand has been weaker than expected, with sales trending below initial forecasts. These variances will require the company to remain agile and responsive to changing dynamics in these key areas.
Long-Term Growth Expectations
Looking further ahead, Tecan retains its optimistic mid-term growth outlook, foreseeing a return to average organic growth rates in the mid- to high-single-digit percentage range under normal market conditions. Although a complete market recovery isn't anticipated until 2026, the company believes that its strong position, bolstered by ongoing healthcare solutions demand, will continue to drive its success.
Profitability Forecast
Tecan has also reiterated its goal of achieving an adjusted EBITDA margin between 17.5% and 18.5% of sales for the full year. These figures consider the potential impact of US tariffs, projected to slightly affect profitability if current trade conditions persist.
About Tecan
Tecan has built a reputation as a pioneer in laboratory automation since its founding in Switzerland in 1980. The company, now with over 3,000 employees globally, specializes in developing innovative solutions that enhance healthcare delivery. In 2024, Tecan demonstrated its financial strength with sales amounting to CHF 934 million.
Recent Developments
To further enhance its service offerings, Tecan continues to invest in product innovations and strategic collaborations that expand its market footprint. The ongoing focus on research and development signifies its commitment to leading healthcare advancements.
Frequently Asked Questions
What was Tecan's sales growth in Q3 2025?
Tecan reported a mid-single-digit growth in sales during the third quarter of 2025.
How did the segments perform in the third quarter?
The Life Sciences Business experienced a mild decline in sales, while the Partnering Business saw an increase in the low teens percentage range.
What is Tecan's outlook for full-year 2025?
Tecan expects its sales for FY 2025 to range from a low single-digit decline to low single-digit growth.
What has Tecan indicated about its mid-term growth?
Tecan maintains a mid-term outlook of returning to average organic growth rates in the mid- to high-single-digit range.
Who can I contact for more information about Tecan?
For inquiries, you can contact Martin Brändle, Senior Vice President, Corporate Communications & IR, at the Tecan Group.
